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Abstract
Aims/hypothesis Angiopoietin-like 4 (ANGPTL4) is an important regulator of triacylglycerol metabolism, carrying out this role
by inhibiting the enzymes lipoprotein lipase and pancreatic lipase. ANGPTL4 is a potential target for ameliorating cardiomet-
abolic diseases. Although ANGPTL4 has been implicated in obesity, the study of the direct role of ANGPTL4 in diet-induced
obesity and related metabolic dysfunction is hampered by the massive acute-phase response and development of lethal chylous
ascites and peritonitis in Angptl4−/− mice fed a standard high-fat diet. The aim of this study was to better characterise the role of
ANGPTL4 in glucose homeostasis and metabolic dysfunction during obesity.
Methods We chronically fed wild-type (WT) and Angptl4−/−mice a diet rich in unsaturated fatty acids and cholesterol, combined
with fructose in drinking water, and studied metabolic function. The role of the gut microbiota was investigated by orally
administering a mixture of antibiotics (ampicillin, neomycin, metronidazole). Glucose homeostasis was assessed via i.p. glucose
and insulin tolerance tests.
Results Mice lacking ANGPTL4 displayed an increase in body weight gain, visceral adipose tissue mass, visceral adipose tissue
lipoprotein lipase activity and visceral adipose tissue inflammation compared with WT mice. However, they also unexpectedly
had markedly improved glucose tolerance, which was accompanied by elevated insulin levels. Loss of ANGPTL4 did not affect
glucose-stimulated insulin secretion in isolated pancreatic islets. Since the gut microbiota have been suggested to influence
insulin secretion, and because ANGPTL4 has been proposed to link the gut microbiota to host metabolism, we hypothesised a
potential role of the gut microbiota. Gut microbiota composition was significantly different between Angptl4−/− mice and WT
mice. Interestingly, suppression of the gut microbiota using antibiotics largely abolished the differences in glucose tolerance and
insulin levels between WT and Angptl4−/− mice.
Conclusions/interpretation Despite increasing visceral fat mass, inactivation of ANGPTL4 improves glucose tolerance, at least
partly via a gut microbiota-dependent mechanism.
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Introduction
Obesity is often accompanied by insulin resistance, which
greatly increases the risk of cardiometabolic complications
[1]. Part of the effect of insulin resistance on cardiometabolic
risk is conferred by changes in plasma lipoproteins. A partic-
ular class of lipoproteins are triacylglycerol-rich lipoproteins,
consisting of chylomicrons and VLDL [2]. Once in the blood,
triacylglycerol-rich lipoproteins are quickly captured and hy-
drolysed by lipoprotein lipase (LPL) in the capillaries of fat
and muscle tissue [3–5]. The resulting fatty acids are taken up
by underlying fat and muscle cells, and are either stored as
triacylglycerols or used as fuel [3]. To ensure that the rate of
uptake of fatty acids matches local energy demands, the activ-
ity of LPL is carefully regulated. An important group of phys-
iological regulators of LPL activity are the angiopoietin-like
proteins, including the ubiquitously expressed angiopoietin-
like 4 (ANGPTL4) [6]. We and others have shown that
ANGPTL4 post-translationally inhibits LPL activity under
various physiological conditions, including fasting and cold
exposure, thereby raising plasma triacylglycerol levels [7–9].
Besides inhibiting LPL, ANGPTL4 also inhibits pancreatic
lipase, the main enzyme responsible for hydrolysis of dietary
triacylglycerols in the gastrointestinal tract and a structural
homologue of LPL. Consequently, mice lacking ANGPTL4
have enhanced dietary lipid absorption compared with wild-
type (WT) mice, contributing to the higher fat mass and body
weight [10].
By reducing fat storage in adipose tissue, ANGPTL4might
promote ectopic fat storage in non-adipose tissues, which in
turn could impact on glucose homeostasis. Indeed, a number
of mouse studies have implicated ANGPTL4 in the regulation
of glucose metabolism. While Angptl4 inactivation did not
influence plasma glucose and insulin levels [11], liver-
specific overexpression of Angptl4 by adenovirus lowered
circulating glucose levels and improved glucose tolerance,
possibly via reduced hepatic glucose production [12, 13]. In
contrast, whole-body transgenic overexpression of Angptl4
decreased glucose tolerance after prolonged high-fat feeding
[14]. In clamp studies, whole-body transgenic Angptl4 over-
expression led to impaired glucose utilisation and insulin re-
sistance in the periphery, and higher insulin-mediated suppres-
sion of glucose production in the liver [15]. Hence, published
data do not present a uniform picture on the influence of
ANGPTL4 on glucose metabolism and insulin sensitivity.
Considering the involvement of ANGPTL4 in fat uptake
and storage, and its potential role in glucose metabolism, it
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metabolic dysfunction and insulin sensitivity during obesi-
ty. Unfortunately, the study of ANGPTL4 in diet-induced
obesity and associated metabolic dysfunction is hampered
by the massive acute phase response and the development
of lethal chylous ascites in Angptl4−/− mice fed a high-fat
diet. This severe inflammatory response is specifically pro-
voked by a diet high in saturated fatty acids [16]. By con-
trast, feeding Angptl4−/− mice a diet rich in cis or trans
unsaturated fatty acids does not trigger an inflammatory
response [17]. Accordingly, in the present paper we inves-
tigated the influence of ANGPTL4 on diet-induced obesity
and metabolic dysfunction by feeding WT and Angptl4−/−
mice a diet rich in unsaturated fatty acids, followed by
detailed investigation of the metabolic phenotype.
Cholesterol was added to the diet and fructose to the drink-
ing water to mimic a western-style diet.
Methods
Animals and diet Animal studies were performed using pure-
bred WT and Angptl4−/− mice on a C57Bl/6 background that
were bred and maintained in the same facility for more than 20
generations [11]. Angptl4−/− mice were generated via homol-
ogous recombination of embryonic stem cells, and lack part of
the Angptl4 gene, resulting in a non-functional ANGPTL4
protein [11]. The Angptl4−/−mice were imported to our animal
facility in 2006 as strain B6.129P2-Lp139tm1 N10 from
Taconic (Germantown, NY, USA; a kind gift of A. Köster,
Eli Lilly, Indianapolis, IN, USA). Mice were individually
housed in temperature- and humidity-controlled specific
pathogen-free conditions. Mice had ad libitum access to food
and water.
In study 1, two groups of mice were studied; male WTand
Angptl4−/− mice at 10–13 weeks of age. These two groups
were part of a larger study (the control groups of this study),
which aimed to investigate the effects of different dietary fi-
bres on non-alcoholic fatty liver disease inWTand Angptl4−/−
mice [18]. The assignment to the different fibre groups was
randomised using an online randomisation tool. Liver fat
levels, liver histology and hepatic expression of genes related
to inflammation (e.g. F4/80 [also known as Adgre1], Cd68,
Mcp-1 [Cxcl2], Il1b, Il1ra [Il1rn], Tnfa [Tnf], Itgax, Timp1)
were all analysed (all were significantly higher in Angptl4−/−
mice compared with WT mice; data not included). A power
calculation was performed based on plasma alanine amino-
transferase (ALT) activity as a biomarker for liver health.
Assuming a plasma ALT activity of 40 U/l in WT mice with
a σ value of 16, using a power of 0.8, a significance level of
0.05, and an effect size of 20 U/l, the sample size was calcu-
lated as n = 11 mice per group. To allow compensation for
potential loss of mice during the study, n = 12 mice were in-
cluded per group. Mice were fed a high-fat/high-cholesterol/
high-fructose diet, providing 45% energy as triacylglycerols
(Formula D12451, Research Diets; manufactured by Research
Diet Services, Wijk bij Duurstede, the Netherlands; sterilised
with γ-irradiation at 9 kGy) for 18 weeks [18–20]. The fat
source of the diet was replaced by safflower oil and supple-
mented with 1% cholesterol (wt/wt) (Dishman, Veenendaal,
the Netherlands). Fructose was administered by adding 20%
fructose (wt/vol.) to the drinking water. After 17 weeks of
dietary intervention, all mice underwent a glucose tolerance
test, as explained below.
In study 2, male WT and Angptl4−/− mice at 19–22 weeks
of age received the same diet as in study 1 (Formula 58V8
a.k.a. D12541; manufactured by TestDiet, Saint Louis, MO,
USA; sterilisedwithγ-irradiation at 18–50 kGy) for 18weeks.
The fat source of the diet was replaced by safflower oil
and supplemented with 1% cholesterol (wt/wt). Fructose
was administered by adding 20% fructose (wt/vol.) to the
drinking water. A mixture of broad-spectrum antibiotics
was provided in the drinking water (1 g/l ampicillin, 1 g/l
neomycin sulfate and 0.5 g/l metronidazole). This antibi-
otic cocktail was previously shown to effectively suppress
intestinal bacteria [21, 22]. Control mice received normal
water. The assignment of the antibiotics/normal water was
randomised using an online randomisation tool. After
15 weeks of dietary intervention, all mice underwent an
intestinal permeability assay (see below for further de-
tails). After 16 weeks, all mice underwent an insulin tol-
erance test, and after 17 weeks a glucose tolerance test, as
explained below. A power calculation was performed
based on the AUC of the glucose tolerance test; assuming
an AUC of 1800 mmol/l × min in WT mice with a σ value
of 150, using a power of 0.8, a significance level of 0.05,
and an effect size of 200 mmol/l × min, the sample size
was calculated as n = 9 mice per group. To allow compen-
sation for potential loss of mice during the study, n = 10
mice were included per group. PCR indicated that two
mice in the WT group treated with antibiotics were in fact
Angptl4−/− mice. These two mice were included in the
group of Angptl4−/− mice on antibiotics.
Body weight and food intake were assessed weekly in both
studies. After 18 weeks, mice were anaesthetised using
isoflurane and blood was collected by orbital puncture. Mice
were euthanised via cervical dislocation, after which tissues
were excised and weighed and intestinal content was sampled.
Samples were immediately frozen in liquid nitrogen and
stored at −80°C. All animal experiments were approved by
the local animal ethics committee of Wageningen University,
the Netherlands. All analyses were conducted with the exper-
imenter blinded to group assignment.
Intraperitoneal glucose tolerance test In both study 1 and 2, a
glucose tolerance test was performed 1 week beforemice were
euthanised. The test was carried out as previously described
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[14]. Briefly, after 5 h of fasting, mice were injected i.p. with
glucose (0.8 g/kg body weight) and blood glucose and insulin
levels were measured at various time points during the test
(see electronic supplementary materials (ESM) Methods for
further details).
Insulin tolerance test In study 2, an insulin tolerance test was
performed 2 weeks before mice were euthanised. The test was
carried out as previously described [14]. Briefly, blood sam-
ples were collected immediately before and at selected time
points after i.p. insulin injection (0.75 U/kg body weight) (see
ESM Methods for further details).
Intestinal permeability assay In study 2, an intestinal perme-
ability assay was performed 3 weeks before euthanasia. FITC-
dextran (4 kD) (Sigma, Houten, the Netherlands) was adminis-
tered by oral gavage (600mg/kg bodyweight, 40mg/ml). After
1 h, blood was drawn, stored on ice in the dark and centrifuged
for 15 min at 1000 g. The plasma obtained was diluted in PBS
and fluorescence intensity was measured using a fluorescence
spectrophotometer (Fluoroskan Ascent; Thermo Fisher
Scientific, Breda, the Netherlands; excitation wavelength
(λex), 485 nm; emission wavelength (λem), 538 nm). FITC-
dextran concentrations were determined using a standard curve
generated by diluting FITC-dextran in PBS. A baseline blood
sample was used to correct for autofluorescence.
Plasma measurements Serum amyloid A was measured via
ELISA (Life technologies, Bleiswijk, the Netherlands), plas-
ma triacylglycerol by a commercially available colourimetric
kit (HUMAN Diagnostics, Wiesbaden, Germany) and endo-
toxin levels via the Limulus Amebocyte Lysate assay (Lonza,
Walkerville, MD, USA).
Cell culture Mouse beta-TC6 cells (CRL11506; ATCC via
LGC [Wesel, Germany]) were grown in 24-well plates in
Dulbecco’s modified Eagle’s medium (DMEM) supplement-
ed with 15% heat-inactivated FCS and 1% penicillin/
streptomycin (Lonza, Verviers, Belgium) under 5% CO2 at
37°C. Cells tested negative for mycoplasma.
RNA isolation and PCRTotal RNAwas extracted from mesen-
teric adipose tissue, beta-TC6 cells and mouse pancreatic is-
lets using TRIzol reagent (Life technologies) and the RNeasy
minikit (Qiagen, Venlo, The Netherlands). RNAwas reverse-
transcribed using the iScript cDNA synthesis kit (Bio-Rad
Laboratories, Veenendaal, the Netherlands). PCR was carried
out as previously described [7] for the following genes: 36b4
(also known as Rplp0), Cd68, F4/80, Mcp-1, Il6, Il1ra, Lpl
and Angptl4. Further details can be found in ESM Methods.
Mouse pancreatic islet isolation Pancreatic islets were isolated
from WT and Angptl4−/− mice by injecting Liberase TL
(Sigma) into the bile duct. Additional details can be found in
ESM Methods.
Glucose-stimulated insulin secretion Groups of 8 islets isolat-
ed fromWTand Angptl4−/−mice were fasted for 1 h, followed
by stimulation with low (2 mmol/l) and high (20 mmol/l)
glucose. Islets were lysed, and secreted insulin and insulin
content was quantified by ELISA (Crystal Chem, Zaandam,
the Netherlands) (see ESM Methods).
1H-NMR spectroscopy Short-chain fatty acid (SCFA) levels in
the content of the caecum were measured using an Avance III
NMR spectrometer (Bruker, Leiderdorp, the Netherlands), as
previously described [18].
Immunohistochemistry Paraffin-embedded pancreas sections
(5 μm) were immunohistochemically stained using anti-
insulin antibody (Insulin (H-86): sc-9168; Santa Cruz
Biotechnology, Dallas, TX, USA; 1:800), followed by a bio-
tinylated goat anti-rabbit antibody (BA-1000; Vector Labs,
Brunschwig Chemie, Amsterdam, the Netherlands; 1:200),
and an avidin-biotin-complex (ABC) coupled to peroxidase
(Vector Labs). Visualisation was carried out using 3,3′-
diaminobenzidine for 5 min. For negative controls, primary
antibodies were omitted.
LPL activity measurements LPL activity in mesenteric white
adipose tissue was quantified using a [3H]oleic acid-labelled
triolein substrate, as previously described [9].
Western blot Western blotting was performed to detect
LPL. Mesenteric fat pads were lysed in ice-cold Pierce
IP lysis buffer (Thermo Fisher Scientific) containing pro-
tease and phosphatase inhibitors (Roche, Almere, the
Netherlands). Lysates were centrifuged to remove fat
droplets before protein separation and immunoblotting
with goat anti-mouse LPL or rabbit anti-goat HSP90
(Cell Signaling, Danvers, MA, USA), both at 1:2000.
Further processing of samples was conducted as outlined
previously [7] and described in ESM Methods.
DNA extraction Faecal samples were resuspended in buffer
and cells were lysed. DNAwas subsequently extracted using
either phenol:chloroform:isoamyl alcohol [25:24:1] or the
Maxwell 16 System (Promega, Madison, WI, USA) (see
ESM Methods).
16S rRNA gene sequencing For 16S ribosomal RNA (rRNA)
gene sequencing, DNA samples were sent to the Broad
Institute of MIT and Harvard (Cambridge, MA, USA) and
processed as previously described [18]. For statistical signifi-
cance, biological relevance and visualisation, the linear dis-
criminant analysis (LDA) effect size (LEfSe) method was
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used. The sequencing data are available from the authors upon
request. Further details are provided in ESM Methods.
Bacterial 16S rRNA gene quantification Real-time PCR was
performed on faecal DNA samples from study 2 to investigate
16S rRNA gene expression, using amplified and purified 16S
rRNA to generate a standard curve (see ESM Methods for
details).
StatisticsData are presented as mean ± SEM, unless otherwise
indicated. Statistical analyses were performed using an un-
paired Student’s t test or two-way ANOVA followed by a
Bonferroni test for post-hoc analysis (GraphPad Software,
La Jolla, CA, USA). A p value <0.05 was considered statisti-
cally significant.
Results
To elicit a phenotype that includes (visceral) obesity, insulin
resistance and non-alcoholic fatty liver disease, in study 1WT
and Angptl4−/− mice were fed a diet rich in unsaturated fatty
acids and cholesterol, complemented with fructose in the
drinking water [18–20]. Plasma serum amyloid A concentra-
tions were low inAngptl4−/−mice fed a diet rich in unsaturated
fatty acids compared with Angptl4−/− mice fed a diet rich in
saturated fatty acids [16, 17], and were not significantly ele-
vated compared with WT mice (Fig. 1a). Angptl4−/− mice
gained more weight and had a higher visceral (mesenteric)
fat mass compared with WT mice, despite a similar level of
food intake (Fig. 1b–d). As expected, LPL activity and the
amount of LPL protein were significantly higher in mesenteric
fat of Angptl4−/−mice compared with WTmice (Fig. 1e, f). In
addition, plasma triacylglycerol levels were significantly low-
er in Angptl4−/− mice than in WT mice (Fig. 1g). Consistent
with the increased body weight and elevated mesenteric fat-
pad weight, Angptl4−/− mice displayed increased inflamma-
tion in mesenteric fat compared with WT mice, as revealed
by higher expression of several inflammatory genes (Fig. 1h).
Loss of ANGPTL4 leads to improved glucose tolerance
Strikingly, despite the higher visceral fat mass and inflamma-
tion, blood glucose levels during the glucose tolerance test
were markedly lower in Angptl4−/− mice than in WT mice
(Fig. 2a). The lower glucose levels in Angptl4−/− mice were
accompanied by elevated fasting plasma insulin levels (Fig.
2b). These data suggest that Angptl4−/−mice are more glucose
tolerant than WT mice, possibly owing to higher plasma in-
sulin levels.
To explore the potential origin of the elevated plasma insu-
lin levels in Angptl4−/− mice, we investigated whether
ANGPTL4 might be expressed in pancreatic islets, together
with LPL, thereby influencing insulin secretion. LPL has been
proposed as a mediator of the effect of dietary lipids on insulin
secretion [23]. However, although Lpl expression was relative-
ly high in primary pancreatic islets and in the beta cell line
beta-TC6, with Ct values of ~21–22, Angptl4 expression was
very low, with Ct values of ~30.5–32 (Fig. 2c, d). Hence, the
effect of ANGPTL4 on glucose tolerance is unlikely to be
mediated by ANGPTL4 produced by beta cells. BioGPS sup-
ports the minimal expression of Angptl4 in the mouse pancreas
(www.biogps.org/, accessed 11 May 2017). Furthermore,
analysis of several microarray datasets (www.ncbi.nlm.nih.
gov/gds) of mouse pancreatic islets (GSE43620), the beta
cell line beta-TC3 (GSE31102) and beta cells from adult mice
(GSE54374) confirmed that Angptl4 is expressed at very low
levels in pancreatic islets and beta cells. Consistent with the
minimal expression of Angptl4 in pancreatic islets, glucose-
stimulated insulin secretion was not significantly altered in
isolated pancreatic islets of Angptl4−/− mice compared with
WTmice (Fig. 2e). In addition, insulin staining of the pancreas
showed no difference in the abundance of pancreatic islets or
insulin staining intensity in WT vs Angptl4−/− mice (Fig. 2f).
Notably, the above data do not exclude a role for circu-
lating ANGPTL4 in the regulation of islet LPL activity, and
in insulin secretion. However, upregulation of LPL activity
in beta cells has been shown to lead to hyperglycaemia
during a glucose tolerance test [24]. Accordingly, it is un-
l i k e l y t h a t t h e ob s e r v e d h y pog l y c a em i a a n d
hyperinsulinaemia in Angptl4−/− mice are linked to loss of
inhibition of LPL activity in islet cells, whether via
ANGPTL4 that is produced in the pancreas or elsewhere.
Together, these findings suggest that ANGPTL4 probably
does not influence plasma insulin levels via a direct effect
on insulin secretion in pancreatic islets.
Loss of ANGPTL4 alters levels of gut-derived metabolites and
changes gut microbial composition Considering that the gut
microbiota may influence insulin secretion [25, 26], and since
ANGPTL4 has been linked to the gut microbiota [27, 28], we
hypothesised a potential role of the gut microbiota in the effect
of loss of ANGPTL4 on insulin levels. To explore the possi-
bility that Angptl4−/− mice have a different gut microbiota to
WT mice, in study 1 we first measured the levels of several
gut-derived metabolites, including luminal succinate and
SCFAs, and plasma lipopolysaccharide (LPS). In the caecum,
the concentration of butyrate was significantly lower in
Angptl4−/− mice than in WT mice (Fig. 3a). Moreover, in the
colon, levels of both propionate and butyrate were significant-
ly lower, and levels of succinate were significantly higher in
Angptl4−/− mice (Fig. 3b). Also, plasma LPS levels were
higher in Angptl4−/− mice than in WT mice, even though
intestinal permeability measured using FITC-dextran was
similar (Fig. 3c, d). Together, these findings suggest a
potential difference in gut microbiota composition between
Angptl4−/− and WT mice.















































































































































































Fig. 2 Loss of ANGPTL4 leads to improved glucose tolerance. (a) i.p.
glucose tolerance test and AUC of WT (white squares) and Angptl4−/−
(black squares) mice 1 week before euthanasia. (b) Fasting plasma insulin
levels. (c–d) Ct values of Lpl andAngptl4 in (c) mouse beta-TC6 cells and
(d) pancreatic islets isolated from C57Bl/6 mice. (e) Glucose-stimulated
insulin secretion in pancreatic islets isolated from WT and Angptl4−/−
mice. Secreted insulin measured in supernatants was normalised to the
protein content in the cell lysate and expressed as percentage of the mean
of levels in WT islets treated with 2 mmol/l glucose. Dark grey bars, low
glucose stimulation (2 mmol/l); light grey bars, high glucose stimulation
(20 mmol/l). Number of biological replicates: WT low glucose, n = 12;
Angptl4−/− low glucose, n = 11; WT high glucose, n = 12; Angptl4−/− low
glucose, n = 10. (f) Representative pictures of pancreas stained for insulin
(brown staining). Scale bar, 200 μm. Insets show a higher magnification
of a pancreatic islet. Data are presented as mean ± SEM (n = 12 mice per
group) except for the data from beta-TC6 cells and pancreatic islets (SD).




















































































































































































Fig. 1 Loss of ANGPTL4 promotes diet-induced obesity and adipose
tissue inflammation. (a) Plasma serum amyloid A (SAA) concentration.
(b) Body weight gain ofWTand Angptl4−/−mice at the end of the dietary
intervention. (c) Mesenteric white adipose tissue (mWAT) weight. (d)
Average food intake per mouse per day during the dietary intervention.
(e) LPL activity and (f) LPL protein levels in mWAT homogenates.
(g) Plasma triacylglycerol levels. (h) Relative expression of inflammatory
genes in mWAT of WT (white bars) and Angptl4−/− mice (black bars).
Gene expression levels of WT mice were set at 1. Data are presented as
mean ± SEM. n = 12 mice per group. **p < 0.01, ***p < 0.001, Student’s
t test
1452 Diabetologia (2018) 61:1447–1458
To further examine the gut microbiota in WT and
Angptl4−/− mice in study 1, we performed 16S rRNA
sequencing. Principal coordinate analysis of unweighted
UniFrac distance demonstrated differential clustering of
microbiome sequences in Angptl4−/− and WT mice (Fig.
3e). The majority of the difference in bacterial commu-
nity between Angptl4−/− and WT mice can be explained
by the phyla Actinobacteria and Firmicutes. Indeed, only
small non-significant differences were observed within
the phyla Bacteroidetes, Deferribacteres and Proteobacteria.
The phylum Actinobacteria was 2.5-fold more abundant
in Angptl4−/− mice, which was mainly accounted for by a
significant increase in the genus Adlercreutzia. While the
relative abundance of the phylum Firmicutes was com-
parable between the genotypes, the genera Lactobacillus
and SMB53 were over-represented in Angptl4−/− mice. In
contrast, consistent with the lower colonic butyrate
levels, the butyrate-producing Allobaculum was less
abundant in Angptl4−/− mice (Fig. 3f–h, ESM Table 1),
whereas the abundance of other butyrate-producing bac-
teria was not different (members of Lachnospiraceae) or
was increased (members of Clostridiaceae family).
Overall, these data indicate that the gut bacterial compo-
sition is significantly different between Angptl4−/− and









































































































































































Fig. 3 Loss of ANGPTL4 alters levels of gut-derived metabolites and
changes gut microbial composition. (a–b) Concentration of acetate, pro-
pionate, butyrate and succinate in (a) the caecum and (b) the colon ofWT
(white bars) and Angptl4−/− (black bars) mice. n = 12 mice per group. (c)
LPS levels (endotoxin units [EU]/ml) in plasma of WT and Angptl4−/−
mice. n = 12 mice per group. (d) Intestinal permeability as assessed by
plasma FITC-dextran concentration 1 h after oral administration. n = 9
mice per group. Data in (a–d) are presented as mean ± SEM. (e) Principal
coordinates analysis plot (grey dots, WT; black dots Angptl4−/−) and box
plots of unweighted UniFrac distances of the intestinal microbiota of WT
(n = 11) and Angptl4−/− (n = 12) mice. The box extends from the 25th to
75th percentiles, the line indicates the median, and a Bonferroni test was
used to plot the whiskers and the outlier (solid black dot). (f–g) Mean
relative abundance of the colonic bacteria (f) at phylum level and (g) at
the lowest identifiable level. (h) Cladogram generated using the linear
discriminant analysis (LDA) effect size (LEfSe) method displaying bac-
terial taxa significantly enriched in WT (green) or Angptl4−/− (red) mice.
The domain bacteria is depicted by the central point and each ring repre-
sents the next lower taxonomic level (phylum to genus). In (g) and (h), the
letter preceding the underscore indicates the taxonomic level: c, class; p,
phylum; o, order; f, family; g, genus; s, species. *p < 0.05, Student’s t test
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Suppression of gut bacteria abolishes the increase in glucose
tolerance in Angptl4−/− mice To further study the impact of
the gut microbiota on the effect of Angptl4 ablation on glucose
tolerance, we repeated the diet-induced obesity study in WT
and Angptl4−/− mice with or without antibiotics in their drink-
ing water (study 2). Antibiotic supplementation significantly
reduced the number of 16S rRNA gene copies in the faeces
(Fig. 4a) and markedly increased caecum weight (Fig. 4b),
indicating an effective suppression of gut bacteria.
Overall body weight gain was higher in Angptl4−/− mice
than WT mice, which reached significance in the absence of
antibiotics (Fig. 4c). In agreement with the first study, in the
absence of antibiotics, Angptl4−/− mice had elevated mesen-
teric fat-pad weight. In contrast, after antibiotic treatment, the
mesenteric fat mass was not significantly different between
Angptl4−/− mice and WT mice (Fig. 4d). Interestingly, in
WT mice, antibiotic treatment increased Angptl4 mRNA
levels in the ileum but not in mesenteric fat tissue, suggesting
intestinal Angptl4 expression is suppressed by the gut bacteria
(Fig. 4e, f).
Concurrent with the elevated fat mass, in the absence of
antibiotics the expression of several inflammatory genes,
including Cd68, Mcp1, Il6 and Il1ra, was elevated in mesen-
teric fat of Angptl4−/− mice compared with WT mice.
However, in the presence of antibiotics the difference in adi-
pose tissue inflammation between the genotypes was largely
abolished (Fig. 4g–j), suggesting that the increased fat mass
and associated elevation of adipose tissue inflammation in
Angptl4−/− mice are partly dependent on the gut bacteria.
Consistent with data presented in Fig. 2a, in study 2
blood glucose levels during the glucose tolerance test were
significantly lower in Angptl4−/− mice than in WT mice
(Fig. 5a). Suppression of the gut bacteria using antibiotics
substantially reduced the differences in blood glucose
levels between the two sets of mice, suggesting a role for
the gut microbiota in the effect of ANGPTL4 on glucose
tolerance (Fig. 5b, c). The lower glucose levels in
Angptl4−/− mice were accompanied by higher plasma
insulin levels (Fig. 5d). Insulin tolerance was not different
between Angptl4−/− and WT mice (Fig. 5e, f), irrespective
of antibiotic treatment (Fig. 5g, h). Overall, our findings
suggest that loss of ANGPTL4 promotes (visceral) obesity
yet, by raising insulin levels, reduces glucose intolerance,
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Fig. 4 Antibiotics largely abolish the difference in adipose tissue inflam-
mation between WTand Angptl4−/− mice. Mice were fed a high-fat/high-
cholesterol/high-fructose diet either without (CTRL) or with (ABX) an-
tibiotic supplementation. (a) 16S rRNA gene copies per g of faeces inWT
and Angptl4−/− mice with or without antibiotic supplementation. WT
mice, white bars; Angptl4−/− mice, black bars. (b) Weight and represen-
tative images of the caecum. (c) Body weight gain at the end of the
dietary intervention with or without antibiotic supplementation.
(d) Weight of mesenteric white adipose tissue (mWAT). (e–f) Relative
mRNA levels of Angptl4 in (e) the ileum or (f) mWAT. (g–j) Relative
expression of the inflammatory genes (g) Cd68, (h) Mcp1, (i) Il6 and (j)
Il1ra in mWAT. Gene expression levels of WT mice fed the control diet
without antibiotic supplementation were set at 1. Data are presented as
mean ± SEM.WTABX, n = 8;WTCTRL, n = 10; Angptl4−/−CTRL, n =
10; Angptl4−/− ABX, n = 12. *p < 0.05, **p < 0.01, ***p < 0.001 vs WT
or as indicated, two-way ANOVAwith Bonferroni post-hoc test
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Discussion
Here we investigated the role of ANGPTL4 in metabolic dys-
function in mice with diet-induced obesity. As shown previ-
ously [9, 10, 16, 29], Angptl4−/− mice gained more weight,
had elevated fat mass, displayed increased adipose LPL activ-
ity and LPL protein abundance, and had lower plasma triac-
ylglycerol levels compared with WT mice. Unexpectedly, de-
spite elevated visceral fat mass and inflammation, mice lack-
ing ANGPTL4 had improved glucose tolerance. Interestingly,
suppression of the gut bacteria using antibiotics largely
abolished the increased glucose tolerance in Angptl4−/− mice.
Together, our results indicate that loss of ANGPTL4 uncou-
ples visceral obesity from glucose intolerance partly via the
gut microbiota (Fig. 6).
In contrast to the well-established function of ANGPTL4 in
lipid metabolism, much less is known about its role in glucose
metabolism. Previously, we found that mice overexpressing
Angptl4 have impaired glucose tolerance and reduced periph-
eral insulin sensitivity [15]. Conversely, Angptl4−/−mice fed a
high (saturated)-fat diet were reported to have improved glu-
cose tolerance [30], although these data were likely confound-
ed by the development of an acute phase response and chylous
ascites [16]. Our present data indicate that, despite being
heavier, mice lacking ANGPTL4 also have improved glucose
tolerance when fed a diet rich in unsaturated fatty acids, in the
absence of an acute phase response.
The improved glucose tolerance in Angptl4−/− mice was
accompanied by elevated insulin levels but not increased in-
sulin sensitivity, suggesting the lower plasma glucose levels
are caused by increased insulin secretion. Since lipids can
potentiate insulin secretion by pancreatic beta cells [23, 31,
32], we hypothesised that the increased insulin levels in
Angptl4−/− mice may be due to increased lipid uptake in beta
cells as a result of loss of LPL inhibition. Interestingly, LPL
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Fig. 5 Antibiotics largely abolish the difference in glucose tolerance be-
tween WTand Angptl4−/− mice. Mice were fed a high-fat/high-cholester-
ol/high-fructose diet either without (CTRL) or with (ABX) antibiotic
supplementation. (a–c) i.p. glucose tolerance tests in WT (white
squares/bars) and Angptl4−/− (black squares/bars) mice fed the diet (a)
without or (b) with antibiotic supplementation. (c) AUC of plasma glu-
cose during the glucose tolerance tests. (d–f) Plasma insulin levels during
the glucose tolerance test in WT (white squares/bars) and Angptl4−/−
(black squares/bars) mice fed the diet, (d) without or (e) with antibiotic
supplementation. (f) AUC of plasma insulin during the glucose tolerance
test. (g–h) Blood glucose levels as a percentage of baseline during an
insulin tolerance test in WT (white squares) and Angptl4−/− (black
squares) mice fed the diet (g) without or (h) with antibiotic supplemen-
tation. Data are presented as mean ± SEM. WTABX, n = 8; WT CTRL,
n = 10; Angptl4−/− CTRL, n = 10; Angptl4−/− ABX, n = 12. *p < 0.05
**p < 0.01 vs WT or as indicated, Student’s t test or two-way ANOVA
with Bonferroni post-hoc test
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primarily within the pancreatic beta cells [33], implying that
LPL is not involved in lipid uptake by the beta cell.
Furthermore, mice with beta cell-specific overexpression of
LPL and increased LPL activity were found to be
hyperglycaemic during a glucose tolerance test [24].
Paradoxically, a similar phenotype was observed in beta
cell-specific LPL knockout mice. Accordingly, it is difficult
to assess the potential role of beta cell LPL in the effect of
ANGPTL4 loss on glucose tolerance and insulin secretion. In
any case, the effects of ANGPTL4 on glucose tolerance are
unlikely to be mediated by beta cell-derived ANGPTL4, as
Angptl4 is minimally expressed in pancreatic islets and beta
cells [34]. In agreement with this notion, loss of ANGPTL4
did not significantly affect glucose-stimulated insulin secre-
tion in isolated pancreatic islets. Furthermore, loss of
ANGPTL4 did not influence the abundance of pancreatic is-
lets or insulin-staining intensity in the islets.
Interestingly, it was reported that chow-fedAngptl4−/−mice
have impaired glucose tolerance resulting from impaired in-
sulin secretion and dysmorphic islets [34]. The reason for the
discrepancy of this finding with our results remains unclear
but could be related to differences in diet. In line with this
notion, whole-body Angptl4-transgenic mice fed chow or a
semi-purified low-fat diet are only marginally glucose intoler-
ant compared with WT mice, yet become highly glucose in-
tolerant on a high-fat diet [14].
Hinting towards a detrimental effect of ANGPTL4 on glu-
cose tolerance in humans, plasma ANGPTL4 levels appear to
be positively correlated with fasting blood glucose levels [35].
Intriguingly, human genetic studies suggest a link between
LPL/ANGPTL4 and glucose metabolism. Specifically, a
gain-of-function variant of LPL was associated with higher
insulin sensitivity, lower fasting glucose and a lower risk of
type 2 diabetes [36]. Conversely, a loss-of-function variant of
LPL was associated with higher risk of type 2 diabetes [36].
Another study found that gain-of-function alleles of LPL and
loss-of-function alleles of ANGPTL4 were associated with
lower risk of type 2 diabetes [37]. Whether these effects are
specifically connected to LPL in beta cells or elsewhere re-
mains unclear.
Our data suggest that the effects of ANGPTL4 loss on
glucose tolerance are partly dependent on the gut micro-
biota. There is growing evidence that alterations in gut
microbiota composition can modulate insulin sensitivity
[27, 38–40] and insulin secretion [25, 26]. For example,
germ-free and antibiotic-treated mice have improved in-
sulin sensitivity compared with conventionally-raised or
untreated mice [38–40]. Furthermore, the difference in
insulin secretion between different mouse strains could
largely be recapitulated via microbial transfer [25]. In hu-
man participants, transfer of faecal microbiota from lean
donors to recipients with the metabolic syndrome in-
creased insulin sensitivity [41].
One microbial family that has been shown to be positively
correlated with plasma insulin levels is Clostridiaceae [25].
Interestingly, compared with WT mice, we found a higher
relative abundance of Clostridiaceae in the colon of
Angptl4−/− mice, concurrent with elevated plasma insulin
levels. However, because certain Clostridiaceae family
members also positively correlate with obesity and other
metabolic perturbations [42, 43], in our study it is difficult
to link Clostridiaceae specifically to increased insulin
secretion. Interestingly, in human participants, ingestion
of the Lactobacillus strain Lactobacillus reuteri for
4 weeks improved glucose-induced insulin secretion
[26]. In our study, colonic abundance of Lactobacillus
was almost 2-fold higher in Angptl4−/− mice (15.82%)
than WT mice (8.82%). It can thus be speculated that an
increase in Lactobacillus might contribute to elevated
insulin levels in Angptl4−/− mice.
The gut microbiota may affect glucose metabolism via
several mechanisms, including via altered production of
SCFAs and LPS. SCFAs may promote insulin secretion
via several mechanisms, including via the intestinal G
protein-coupled receptor 43 (GPCR43), either dependent
[44] or independent [45] of glucagon-like peptide 1 (GLP-1)
secretion. In addition, acetate may increase glucose-stimulated
insulin secretion via activation of the parasympathetic nervous
system [46]. In our study, however, improved glucose
tolerance in Angptl4−/− mice was associated with lower
SCFA levels in the caecum (butyrate) and colon (propionate
and butyrate).
Another candidate that may link the gut microbiota to
glucose tolerance is LPS. In our study, elevated plasma










Fig. 6 Loss of ANGPTL4 uncouples visceral adiposity from glucose
intolerance partly via the gut microbiota. Schematic diagram of the effects
of ANGTL4 loss on glucose homeostasis. ANGPTL4 loss raises plasma
insulin levels and reduces glucose intolerance via a mechanism that is at
least partly dependent on the gut microbiota. Loss of ANGPTL4 also
increases visceral adipose tissue mass. Hence, loss of ANGPTL4
uncouples visceral obesity from glucose intolerance. Solid lines,
confirmed mechanisms; dashed lines, potential mechanisms
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higher circulating LPS levels vs WT controls. However,
conflicting results exist on the role of LPS in insulin se-
cretion, showing an inhibitory and stimulatory effect [47,
48]. Another study reported that LPS does not affect plas-
ma insulin levels [38], rendering it difficult to link the
higher LPS levels in Angptl4−/− mice to elevated plasma
insulin levels. Hence, SCFA and LPS are probably not
involved in the effect of the gut bacteria on insulin levels
in Angptl4−/− mice.
Interestingly, we found an increased abundance of equol-
producing bacteria, including the Coriobacteriaceae family,
specifically of the genus Adlercreutzia, and Lactobacillus
[49]. As equol improves glucose tolerance [50], improved
glucose tolerance in Angptl4−/− mice might be caused by al-
tered production of equol. However, future studies should
investigate the role of equol and other potential candidates
outlined in this study in regulating insulin levels and glucose
tolerance.
In conclusion, we show that loss of ANGPTL4 in mice
with diet-induced obesity promotes visceral obesity while im-
proving glucose tolerance. Suppression of the gut bacteria by
antibiotics largely abolished differences in glucose tolerance
betweenWTand Angptl4−/−mice, suggesting that ANGPTL4
influences glucose tolerance partly via the gut bacteria.
Further studies are warranted to provide additional evidence
to support the targeting of ANGPTL4 in the treatment of met-
abolic disorders.
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